Possibility of the involvement of 9H-pyrido[3,4-b]indole (norharman) in carcinogenesis via inhibition of cytochrome P450-related activities and intercalation to DNA

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 541, Issue 1-2, 2003, Pages 123-136

  Nii, Hiroaki ^a  

^a GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Comutagenic effect; N Hydroxylation; Noncompetitive inhibition of cytochrome P 450; Norharman

Indexed keywords

AFLATOXIN B1; BETA CARBOLINE; CYTOCHROME P450 1A; CYTOCHROME P450 ISOENZYME; DNA; HETEROCYCLIC AMINE; NITROSAMINE; POLYCHLORINATED BIPHENYL; QUINOXALINE; 2 AMINO 6 METHYLDIPYRIDO(1,2 A 3',2' D)IMIDAZOLE; 2 HYDROXYAMINO 6 METHYLDIPYRIDO(1,2 A 3',2' D)IMIDAZOLE; 2-AMINO-6-METHYLDIPYRIDO(1,2-A-3',2'-D)IMIDAZOLE; 2-HYDROXYAMINO-6-METHYLDIPYRIDO(1,2-A-3',2'-D)IMIDAZOLE; CARCINOGEN; CYTOCHROME P450; DNA TOPOISOMERASE; DRUG DERIVATIVE; HARMINE; IMIDAZOLE DERIVATIVE; INTERCALATING AGENT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CHEMICAL CARCINOGENESIS; COCARCINOGENESIS; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG INHIBITION; DRUG TRANSFORMATION; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME INHIBITION; INTERCALATION COMPLEX; MALE; MUTAGENICITY; NONHUMAN; PRIORITY JOURNAL; RAT; XENOBIOTIC METABOLISM; ANIMAL; DOSE RESPONSE; DRUG ANTAGONISM; SPRAGUE DAWLEY RAT;

ANIMALS; CARCINOGENS; CYTOCHROME P-450 ENZYME SYSTEM; DNA TOPOISOMERASES, TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; HARMINE; IMIDAZOLES; INTERCALATING AGENTS; MALE; NADPH-FERRIHEMOPROTEIN REDUCTASE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 1642321287     PISSN: 13835718     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrgentox.2003.08.001     Document Type: Article

References (83)

1. Airaksinen M.M., Kari I. β-Carbolines, psychoactive compounds in the mammalian body. Part I: Occurrence, origin and metabolism. Med. Biol. 59:1981;21-34.
2. Rommelspacher H., Schmidt L.G., May T. Plasma norharman (β-carboline) levels are elevated in chronic alcoholics. Alcohol Clin. Exp. Res. 15:1991;553-559.
3. Adachi J., Mizoi Y., Naito T., Ogawa Y., Uetani Y., Ninomiya I. Identification of tetrahydro-β-carboline-3-carboxylic acid in foodstuffs, human urine and human milk. J. Nutr. 121:1991;646-652.
4. Totsuka Y., Ushiyama H., Ishihara J., Sinha R., Goto S., Sugimura T., Wakabayashi K. Quantification of the co-mutagenic β-carbolines, norharman and harman, in cigarette smoke condensates and cooked foods. Cancer Lett. 143:1999;139-143.
5. Oda Y., Nakamura S., Oki I. Harman and norharman induce SOS responses and frameshift mutations in bacteria. Mutat. Res. 208:1988;39-44.
6. de Meester C. Genotoxic potential of β-carbolines: a review. Mutat. Res. 339:1995;139-153.
7. Mori M., Totsuka Y., Fukutome K., Yoshida T., Sugimura T., Wakabayashi K. Formation of DNA adducts by the co-mutagen norharman with aromatic amines. Carcinogenesis. 17:1996;1499-1503.
8. Totsuka Y., Hada N., Matsumoto K., Kawahara N., Murakami Y., Yokoyama Y., Sugimura T., Wakabayashi K. Structural determination of a mutagenic aminophenylnorharman produced by the co-mutagen norharman with aniline. Carcinogenesis. 19:1998;1995-2000.
9. Hagiwara A., Sano M., Asakawa E., Tanaka H., Hasegawa R., Ito N. Enhancing effects of harman and norharman on induction of preneoplastic and neoplastic kidney lesions in rats initiated with N-ethyl-N- hydroxyethylnitrosamine. Jpn. J. Cancer Res. 83:1992;949-954.
10. Zajdela F., Perin Roussel O., Saguem S. Marked differences between mutagenicity in Salmonella and tumour-initiating activities of dibenzo[a,e]fluoranthene proximate metabolites initiation inhibiting activity of norharman. Carcinogenesis. 8:1987;461-464.
11. Hagiwara A., Tanaka H., Kurata Y., Kato T., Tsuda H., Ito N. Lack of hepatotoxicity or promotion of enzyme-altered liver foci development in rats treated with harman or norharman. J. Toxicol. Environ. Health. 29:1990;211-218.
12. Hagiwara A., Arai M., Hirose M., Nakanowatari J.I., Tsuda H., Ito N. Chronic effects of norharman in rats treated with aniline. Toxicol. Lett. 6:1980;71-75.
13. Hayashi K., Nagao M., Sugimura T. Interactions of norharman and harman with DNA. Nucl. Acids Res. 4:1977;3679-3685.
14. Chang C.C., Castellazzi M., Glover T.W., Trosko J.E. Effects of harman and norharman on spontaneous and ultraviolet light-induced mutagenesis in cultured Chinese hamster cells. Cancer Res. 38:1978;4527-4533.
15. Shimoi K., Kawabata H., Tomita I. Enhancing effect of heterocyclic amines and β-carbolines on UV or chemically induced mutagenesis in E. coli. Mutat. Res. 268:1992;287-295.
16. Shimoi K., Miyamura R., Mori T., Todo T., Ohtsuka E., Wakabayashi K., Kinae N. 3-Amino-1,4-dimethyl-5H-pyrido[4,3-b]indole (Trp-P-1) inhibits the binding activity of T4 endonuclease V to UV-damaged DNA. Carcinogenesis. 17:1996;1279-1283.
17. Wakabayashi K., Yahagi T., Nagao M., Sugimura T. Comutagenic effect of norharman with aminopyridine derivatives. Mutat. Res. 105:1982;205-210.
18. Sasaki Y.F., Shirasu Y. Suppressing effects of S phase post-treatment with carbolines on sister-chromatid exchanges induced by mitomycin C in Chinese hamster cells. Mutat. Res. 302:1993;165-171.
19. Ashby J., Elliott B.M., Styles J.A. Norharman and ellipticine: a comparison of their albilities to interact with DNA in vitro. Cancer Lett. 9:1980;21-33.
20. Rommelspacher H., May T., Salewski B. Harman (1-methyl-β-carboline) is a natural inhibitor of monoamine oxidase type A in rats. Eur. J. Pharmacol. 252:1994;51-59.
21. Razzouk C., Roberfroid M.B. Species differences in the biochemical properties of liver microsomal arylamine and arylamide N-hydroxylases. Chem. Biol. Interact. 41:1982;251-264.
22. Yoshihara S., Tatsumi K. Purification and characterization of hepatic aldehyde oxidase in male and female mice. Arch. Biochem. Biophys. 338:1997;29-34.
23. Fujino T., Matsuyama A., Nagao M., Sugimura T. Inhibition by norharman of metabolism of benzo[a]pyrene by the microsomal mixed-function oxidase of rat liver. Chem. Biol. Interact. 32:1980;1-12.
24. Kuhn Velten W.N. Norharman (β-carboline) as a potent inhibitory ligand for steroidogenic cytochromes P450 (CYP11 and CYP17). Eur. J. Pharmacol. 250:1993;R1-3.
25. Bulleid N.J., Craft J.A. Effects of metyrapone and norharmane on microsomal mono-oxygenase and epoxide hydrolase activities. Biochem. Pharmacol. 33:1984;1451-1457.
26. 32P -postlabeling analysis of inhibition by norharman of formation of dibenzo[a,e]fluoranthene - DNA adducts in mouse embryo fibroblasts Carcinogenesis. 13:1992;723-725.
27. Sono M., Cady S.G. Enzyme kinetic and spectroscopic studies of inhibitor and effector interactions with indoleamine 2,3-dioxygenase. 1. Norharman and 4- phenylimidazole binding to the enzyme as inhibitors and heme ligands. Biochemistry. 28:1989;5392-5399.
28. Hashimoto Y., Shudo K., Okamoto T. Modification of DNA with potent mutacarcinogenic 2-amino-6-methyldipyrido[1,2-a:3′,2′-d]imidazole isolated from a glutamic acid pyrolysate: structure of the modified nucleic acid base and initial chemical event caused by the mutagen. J. Am. Chem. Soc. 104:1982;7636-7640.
29. Mori H., Tanaka T., Sugie S., Kuniyasu T., Iwata H., Ni-i H., Nishiwaki A., Mori Y. Hepatocarcinogenic activities of hydroxymethyl derivatives of 4-(N,N-dimethylamino)azobenzene in ACI/N rats. J. Natl. Cancer Inst. 79:1987;1159-1161.
30. Mori Y., Niwa T., Takahashi H., Toyoshi K., Denda A., Takahashi S., Konishi Y. Mutagenicity of N-nitrosobis(2-hydroxypropyl)amine and its related compounds in the presence of rat lung and liver S9. Cancer Lett. 18:1983;271-275.
31. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
32. Burke M.D., Thompson S., Weaver R.J., Wolf C.R., Mayer R.T. Cytochrome P450 specificities of alkoxyresorufin O-dealkylation in human and rat liver. Biochem. Pharmacol. 48:1994;923-936.
33. Rutten A.A., Falke H.E., Catsburg J.F., Wortelboer H.M., Blaauboer B.J., Doorn L., Leeuwen F.X.R.V., Theelen R., Rietjens I.M.C.M. Interlaboratory comparison of microsomal ethoxyresorufin and pentoxyresorufin O-dealkylation determinations: standardization of assay conditions. Arch. Toxicol. 66:1992;237-244.
34. Nebbia C., Dacasto M., Ceppa L., Burdino E., Witkamp R.F., Ugazio G. Gender differences in ethanol oxidation and cytochrome P4502E1 content and functions in hepatic microsomes from alcohol-preferring and non-preferring rats. Xenobiotica. 26:1996;1121-1129.
35. Beyeler S., Testa B., Perrissoud D. The effect of cianidanol on rat hepatic monooxygenase activities. Arzneimittelforschung. 33:1983;564-567.
36. Phillips A.H., Langdon R.G. Hepatic triphosphopyridine nucleotide-cytochrome c reductase isolation, characterization, and kinetic studies. J. Biol. Chem. 237:1962;2652-2660.
37. Habig W.H., Pabst M.J., Jakoby W.B. Glutathione S-transferases. J. Biol. Chem. 249:1974;7130-7139.
38. Burchell B., Weatherill P. 4-Nitrophenol UDP-glucuronyltransferase (rat liver). Meth. Enzymol. 77:1981;169-177.
39. Maron D.M., Ames M.N. Revised methods for the Salmonella mutagenicity test. Mutat. Res. 113:1983;172-215.
40. Fisher L.M., Kuroda R., Sakai T.T. Interaction of bleomycin A2 with deoxyribonucleic acid: DNA unwinding and inhibition of bleomycin-induced DNA breakage by cationic thiazole amides related to bleomycin A2. Biochemistry. 24:1985;3199-3207.
41. Omura T., Sato R. The carbon monooxide-binding pigment of liver microsomes. J. Biol. Chem. 239:1964;2370-2378.
42. Lin D.X. Effects of harman and norharman on aflatoxin B1 and aminopyrene metabolism by phenobarbital and 3-methylcholanthrene-induced rat liver microsomes. Chung Hua Yu Fang I Hsueh Tsa Chih. 26:1992;209-212.
43. Kuhn-Velten W.N. Norharman (β-carboline) as a potent inhibitory ligand for steroidogenic cytochromes P450 (CYP11 and CYP17). Eur. J. Pharmacol. 250:1993;R1-3.
44. 3H ] β-carboline) to the ethanol-inducible cytochrome P450 2E1 in rat liver Biochem. Pharmacol. 57:1999;511-520.
45. Kato R., Yamazoe Y. Metabolic activation and covalent binding to nucleic acids of carcinogenic heterocyclic amines from cooked foods and amino acid pyrolysates. Jpn. J. Cancer Res. 78:1987;297-311.
46. Degawa M., Ueno H., Miura S., Ohta A., Namiki M. A simple method for assessment of rat cytochrome P-448 isozymes responsible for the mutagenic activation of carcinogenic chemicals. Mutat. Res. 203:1988;333-338.
47. Kawamori T., Totsuka Y., Ishihara J., Uchiya N., Sugimura T., Wakabayashi K. Induction of liver preneoplastic lesions by aminophenylnorharman, formed from norharman and aniline, in male F344 rats. Cancer Lett. 163:2001;157-161.
48. Ohnishi S., Murata M., Oikawa S., Totsuka Y., Takamura T., Wakabayashi K., Kawanishi S. Oxidative DNA damage by an N-hydroxy metabolite of the mutagenic compound formed from norharman and aniline. Mutat. Res. 494:2001;63-72.
49. Ohe T., Takata T., Maeda Y., Totsuka Y., Hada N., Matsuoka A., Tanaka N., Wakabayashi K. Induction of sister chromatid exchanges and chromosome aberrations in cultured mammalian cells treated with aminophenylnorharman formed by norharman with aniline. Mutat. Res. 515:2002;181-188.
50. Elliott B.M. Azoreductase activity of Sprauge-Dawley and Wistar-derived rats towards both carcinogenic and non-carcinogenic analogues of 4-dimethylaminophenylazobenzene (DAB). Carcinogenesis. 5:1984;1051-1055.
51. Funayama Y., Nishio K., Wakabayashi K., Nagao M., Shimoi K., Ohira T., Hasegawa S., Saijo N. Effects of β- and γ-carboline derivatives of DNA topoisomerase activities. Mutat. Res. 349:1996;183-191.
52. Tohda H., Tada M., Sugawara R., Oikawa A. Actions of amino-β- carbolines on induction of sister-chromatid exchanges. Mutat. Res. 116:1983;137-147.
53. Sato H., Matsuda K., Iijama H., Kawahara T., Takahashi M. Clastogenicity of norharman in cultured Chinese hamster cells. Mutat. Res. 252:1991;105. (abstract).
54. Johnson F.B. Chemical interactions with herpes simplex type 2 virus: enhancement of transformation by norharman. Carcinogenesis. 3:1982;457-459.
55. 3H ]β-carboline)-binding proteins from rat liver J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 784:2003;155-168.
56. Saito K., Shinohara A., Kamataki T., Kato R. Metabolic activation of mutagenic N-hydroxyarylamines by O-acetyltransferase in Salmonella typhimurium TA98. Arch. Biochem. Biophys. 239:1985;286-295.
57. Sugimura T., Nagao M., Wakabayashi K. Metabolic aspects of the comutagenic action of norharman. Adv. Exp. Med. Biol. 136(Pt B):1981;1011-1025.
58. Nagao M., Yahagi T., Sugimura T. Differences in effects of norharman with various classes of chemical mutagens and amounts of S-9. Biochem. Biophys. Res. Commun. 83:1978;373-378.
59. Snyderwine E.G., Roller P.P., Wirth P.J., Adamson R.H., Sato S., Thorgeirsson S.S. Synthesis, purification and mutagenicity of 2-hydroxyamino-3-methylimidazo[4,5-f]quinoline. Carcinogenesis. 8:1987;1017-1020.
60. Perin-Roussel O., Ekert B., Zajdela F. Apparent stimulation of dibenzo[a,e]fluoranthene in vitro metabolism in the presence of norharman. Chem. Biol. Interact. 37:1981;109-122.
61. Fekkes D., Bode W.T. Occurrence and partition of the β-carboline norharman in rat organs. Life Sci. 52(25):1993;2045-2054.
62. Nishikawa A., Furukawa F., Imazawa T., Yoshimura H., Ikezaki S., Hayashi Y., Takahashi M. Effects of cigarette smoke on N-nitrosobis(2-oxopropyl)amine- induced pancreatic and respiratory tumorigenesis in hamsters. Jpn. J. Cancer Res. 85:1994;1000-1004.
63. Nishikawa A., Furukawa F., Miyauchi M., Son H.Y., Okazaki K., Koide A., Mori Y., Hirose M. Enhancement by cigarette smoke exposure of 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline-induced rat hepatocarcinogenesis in close association with elevation of hepatic CYP1A2. Jpn. J. Cancer Res. 93:2002;24-31.
64. Mori Y., Iimura K., Furukawa F., Nishikawa A., Takahashi M., Konishi Y. Effect of cigarette smoke on the mutagenic activation of various carcinogens in hamster. Mutat. Res. 346:1995;1-8.
65. Koide A., Fuwa K., Furukawa F., Hirose M., Nishikawa A., Mori Y. Effect of cigarette smoke on the mutagenic activation of environmental carcinogens by rodent liver. Mutat. Res. 428:1999;165-176.
66. Suzuki S., Takahashi S., Asamoto M., Inaguma S., Ogiso T., Hirose M., Shirai T. Lack of modification of 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx)-induced hepatocarcinogenesis in rats by fenbendazole - a CYP1A2 inducer. Cancer Lett. 185:2002;39-45.
67. Lee C.K., Fulp C., Bombick B.R., Doolittle D.J. Inhibition of mutagenicity of N-nitrosamines by tobacco smoke and its constituents. Mutat. Res. 367:1996;83-92.
68. Mori Y., Yamazaki H., Toyoshi K., Makino T., Obara T., Yokose Y., Konishi Y. Mutagenic activation of carcinogenic N-nitrosopropylamines by rat liver: evidence for a cytochrome P-450 dependent reaction. Carcinogenesis. 6:1985;415-420.
69. Kazakoff K., Iversen P., Lawson T., Baron J., Guengerich F.P., Pour P.M. Involvement of cytochrome P450 2E1-like isoform in the activation of N-nitrosobis(2-oxopropyl)amine in the rat nasal mucosa. Eur. J. Cancer. B Oral Oncol. 30B:1994;179-185.
70. Brown B., Avalos J., Lee C., Doolittle D. The effect of tobacco smoke, nicotine, and cotinine on the mutagenicity of 4-(methylnitrosamino)-1-(3- pyridyl)-1-butanol (NNAL). Mutat. Res. 494:2001;21-29.
71. Herraiz T. Identification and occurrence of the bioactive β-carbolines norharman and harman in coffee brews. Food Addit. Contam. 19:2002;748-754.
72. Kuhn W., Muller T., Grosse H., Rommelspacher H. Plasma harman and norharman in Parkinson's disease. J. Neural Transm. Suppl. 46:1995;291-295.
73. Wodarz N., Wiesbeck G.A., Rommelspacher H., Riederer P., Boning J. Excretion of β-carbolines harman and norharman in 24-h urine of chronic alcoholics during withdrawal and controlled abstinence. Alcohol Clin. Exp. Res. 20:1996;706-710.
74. Wakabayashi K., Totsuka Y., Fukutome K., Oguri A., Ushiyama H., Sugimura T. Human exposure to mutagenic/carcinogenic heterocyclic amines and comutagenic β-carbolines. Mutat. Res. 376(1-2):1997;253-259.
75. Rommelspacher H., Meier-Henco M., Smolka M., Kloft C. The levels of norharman are high enough after smoking to affect monoamineoxidase B in platelets. Eur. J. Pharmacol. 441:2002;115-125.
76. 3H ]β-carboline) binds reversibly and with high affinity to a specific binding site in rat liver Neurochem. Res. 18:1993;1029-1031.
77. Guengerich F.P., Mason P.S. Immunological comparison of hepatic and extrahepatic cytochromes P-450. Mol. Pharmacol. 15:1979;154-164.
78. Rich K.J., Sesardic D., Foster J.R., Davies D.S., Boobis A.R. Immunohistochemical localization of cytochrome P450b/e in hepatic and extrahepatic tissues of the rat. Biochem. Pharmacol. 38:1989;3305-3322.
79. Sesardic D., Cole K.J., Edwards R.J., Davies D.S., Thomas P.E., Levin W., Boobis A.R. The inducibility and catalytic activity of cytochromes P450c (P450IA1) and P450d (P450IA2) in rat tissues. Biochem. Pharmacol. 39:1990;499-506.
80. Windmill K.F., McKinnon R.A., Zhu X., Gaedigk A., Grant D.M., McManus M.E. The role of xenobiotic metabolizing enzymes in arylamine toxicity and carcinogenesis: functional and localization studies. Mutat. Res. 376:1997;153-160.
81. Brockmoller J., Cascorbi I., Kerb R., Sachse C., Roots I. Polymorphisms in xenobiotic conjugation and disease predisposition. Toxicol. Lett. 102-103:1998;173-183.
82. Bartsch H., Nair U., Risch A., Rojas M., Wikman H., Alexandrov K. Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. Cancer Epidemiol. Biomarkers Prev. 9:2000;3-28.
83. Le Marchand L., Hankin J.H., Wilkens L.R., Pierce L.M., Franke A., Kolonel L.N., Seifried A., Custer L.J., Chang W., Lum-Jones A., Donlon T. Combined effects of well-done red meat, smoking, and rapid N-acetyltransferase 2 and CYP1A2 phenotypes in increasing colorectal cancer risk. Cancer Epidemiol. Biomarkers Prev. 10:2001;1259-1266.